Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Fufang Moshizi Ruangao is a traditional Uighur medicine (TUM) developed and manufactured by Xinqikang Pharmaceutical Co., Ltd. for the treatment of pediatric eczema. Formulated as a topical ointment, its primary active ingredient is derived from *Galla Turcica* (Moshizi), which is exceptionally rich in tannins and phenolic compounds. These components provide potent astringent, anti-inflammatory, and antimicrobial properties, which are effective in reducing skin exudation, alleviating pruritus (itching), and promoting the healing of skin lesions in children. It is specifically indicated for the subacute and chronic stages of eczema and serves as a non-corticosteroid therapeutic alternative in Chinese pediatric dermatology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaoer fufang moshizi ruangao.